PA8483301A1 - Concentrado oral de sertralina - Google Patents
Concentrado oral de sertralinaInfo
- Publication number
- PA8483301A1 PA8483301A1 PA19998483301A PA8483301A PA8483301A1 PA 8483301 A1 PA8483301 A1 PA 8483301A1 PA 19998483301 A PA19998483301 A PA 19998483301A PA 8483301 A PA8483301 A PA 8483301A PA 8483301 A1 PA8483301 A1 PA 8483301A1
- Authority
- PA
- Panama
- Prior art keywords
- provides
- present
- sertralina
- concentrated
- aqueous
- Prior art date
Links
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 3
- 239000012141 concentrate Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 229960002073 sertraline Drugs 0.000 abstract 2
- -1 3,4-DICHLOROPHENYL Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UNA COMPOSICIÓN FARMACÉUTICA CONCENTRADA, LÍQUIDA, ESENCIALMENTE NO ACUOSA, PARA LA ADMINISTRACIÓN ORAL, QUE CONTIENE SERTRALINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA Y UNO O MÁS EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA UN USO DE ESTA COMPOSICIÓN CONCENTRADA PARA PREPARAR UNA SOLUCIÓN ACUOSA DE SERTRALINA. ADEMÁS, LA PRESENTE INVENCIÓN PROPORCIONA UN PROCEDIMIENTO DE USO DE ESTA COMPOSICIÓN CONCENTRADA PARA TRATAR O PREVENIR UNA DIVERSIDAD DE ENFERMEDADES O AFECCIONES. FINALMENTE, LA PRESENTE INVENCIÓN PROPORCIONA EL COMPUESTO METANOSULFONATO DE (1S-CIS)- 4-(3,4-DICLOROFENIL)-1,2.3.4-TETRAHIDRO-N-METIL-1-NAFTALENOAMINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10402498P | 1998-10-13 | 1998-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8483301A1 true PA8483301A1 (es) | 2000-09-29 |
Family
ID=22298286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA19998483301A PA8483301A1 (es) | 1998-10-13 | 1999-09-28 | Concentrado oral de sertralina |
Country Status (45)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1225881T1 (sl) | 1999-09-03 | 2006-06-30 | Apbi Holdings Llc | Uporaba dapoksetina, selektivnega zaviralca ponovnega privzema serotonina s hitrim pricetkom delovanja, za zdravljenje seksualne disfunkcije |
| US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| WO2004065348A1 (en) * | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| US7186863B2 (en) | 2003-05-23 | 2007-03-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
| WO2005034910A1 (en) * | 2003-10-08 | 2005-04-21 | Ranbaxy Laboratories Limited | Oral liquid pharmaceutical compositions of sertraline |
| WO2007052152A2 (en) * | 2005-11-07 | 2007-05-10 | Aurobindo Pharma Limited | Sertraline oral concentrate |
| US20080268067A1 (en) * | 2007-03-09 | 2008-10-30 | Llinas Rodolfo R | Methods and Compositions for Treating Thalamocortical Dysrhythmia |
| CN109908354A (zh) * | 2017-12-12 | 2019-06-21 | 万特制药(海南)有限公司 | 盐酸舍曲林口服浓缩液及其制备工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4940731A (en) * | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
| US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
| ATE96999T1 (de) * | 1989-08-30 | 1993-11-15 | Pfizer | Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen. |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| SE508372C2 (sv) * | 1995-02-13 | 1998-09-28 | Kjell Lindstroem | Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar |
| EP0768083B1 (en) * | 1995-07-17 | 2003-03-26 | Pfizer Inc. | Sertraline for treating post myocardial infarction patients |
| ID24673A (id) * | 1997-07-01 | 2000-07-27 | Pfizer Prod Inc | Bentuk-bentuk penakaran larutan sertralina dalam kapsul gelatin |
-
1999
- 1999-09-22 EE EEP200100221A patent/EE04868B1/xx not_active IP Right Cessation
- 1999-09-22 ES ES99943168T patent/ES2209490T3/es not_active Expired - Lifetime
- 1999-09-22 KR KR10-2001-7004559A patent/KR100417200B1/ko not_active Expired - Fee Related
- 1999-09-22 WO PCT/IB1999/001571 patent/WO2000021521A2/en not_active Ceased
- 1999-09-22 CA CA002346335A patent/CA2346335C/en not_active Expired - Fee Related
- 1999-09-22 AP APAP/P/2001/002119A patent/AP2001002119A0/en unknown
- 1999-09-22 ID IDW20010824A patent/ID29845A/id unknown
- 1999-09-22 GE GEAP19995852A patent/GEP20032969B/en unknown
- 1999-09-22 PL PL99348119A patent/PL348119A1/xx not_active Application Discontinuation
- 1999-09-22 TR TR2001/01090T patent/TR200101090T2/xx unknown
- 1999-09-22 SK SK458-2001A patent/SK4582001A3/sk unknown
- 1999-09-22 OA OA1200100087A patent/OA11662A/en unknown
- 1999-09-22 YU YU26401A patent/YU26401A/sh unknown
- 1999-09-22 BR BR9914418-2A patent/BR9914418A/pt not_active Application Discontinuation
- 1999-09-22 HU HU0104470A patent/HUP0104470A3/hu unknown
- 1999-09-22 EA EA200100285A patent/EA003990B1/ru not_active IP Right Cessation
- 1999-09-22 AU AU56436/99A patent/AU766202B2/en not_active Ceased
- 1999-09-22 CN CNB998120871A patent/CN1184962C/zh not_active Expired - Fee Related
- 1999-09-22 PT PT99943168T patent/PT1121107E/pt unknown
- 1999-09-22 AT AT99943168T patent/ATE254453T1/de not_active IP Right Cessation
- 1999-09-22 CZ CZ20011286A patent/CZ20011286A3/cs unknown
- 1999-09-22 JP JP2000575497A patent/JP3792514B2/ja not_active Expired - Fee Related
- 1999-09-22 HK HK02101974.6A patent/HK1040199B/zh not_active IP Right Cessation
- 1999-09-22 DE DE69912978T patent/DE69912978T2/de not_active Expired - Fee Related
- 1999-09-22 UA UA2001042450A patent/UA72743C2/uk unknown
- 1999-09-22 EP EP99943168A patent/EP1121107B1/en not_active Expired - Lifetime
- 1999-09-22 DK DK99943168T patent/DK1121107T3/da active
- 1999-09-22 HR HR20010263A patent/HRP20010263B1/xx not_active IP Right Cessation
- 1999-09-22 NZ NZ510756A patent/NZ510756A/en unknown
- 1999-09-28 PA PA19998483301A patent/PA8483301A1/es unknown
- 1999-10-05 GT GT199900171A patent/GT199900171A/es unknown
- 1999-10-06 TW TW088117244A patent/TWI228043B/zh not_active IP Right Cessation
- 1999-10-08 AR ARP990105116A patent/AR014082A1/es unknown
- 1999-10-09 GC GCP1999314 patent/GC0000175A/en active
- 1999-10-11 MY MYPI99004384A patent/MY122477A/en unknown
- 1999-10-11 PE PE1999001025A patent/PE20001108A1/es not_active Application Discontinuation
- 1999-10-12 DZ DZ990213A patent/DZ2913A1/xx active
- 1999-10-12 MA MA25814A patent/MA26698A1/fr unknown
- 1999-10-12 TN TNTNSN99190A patent/TNSN99190A1/fr unknown
- 1999-10-12 EG EG127599A patent/EG23818A/xx active
- 1999-10-13 CO CO99065089A patent/CO5150213A1/es unknown
-
2001
- 2001-03-23 IS IS5906A patent/IS2239B/is unknown
- 2001-04-09 ZA ZA200102900A patent/ZA200102900B/xx unknown
- 2001-04-10 NO NO20011829A patent/NO20011829L/no not_active Application Discontinuation
- 2001-04-10 BG BG105434A patent/BG65085B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| CU23260B7 (es) | PREPARADO FARMACéUTICO DE MOXIFLOXACINA | |
| PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
| GT199900015A (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| BR0113590A (pt) | 7-oxo-piridopirimidinas | |
| PA8483301A1 (es) | Concentrado oral de sertralina | |
| AR030630A1 (es) | Composiciones farmaceuticas | |
| CO5210869A1 (es) | Una combinacion sinergetica: gabapentina y pregabalina | |
| BR0111743A (pt) | Farnesil transferase que inibe enantiÈmero de quinolina 1,2-anelada | |
| RU96120655A (ru) | Композиция для профилактики и лечения гриппа и орви | |
| BR9911756A (pt) | Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto | |
| ECSP993166A (es) | Concentrado oral de sertralina | |
| BR0011845A (pt) | Complexo farmacêutico | |
| PT768083E (pt) | Sertralina para o tratamento de doentes pos-enfarte miocardico | |
| BR9906975A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero | |
| BR0212077A (pt) | Compostos de aminopirróis como agentes antiinflamatórios | |
| AR008154A1 (es) | Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion. | |
| AR022348A1 (es) | Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior | |
| ES2188232T3 (es) | Uso de cetirizina para impedir la aparicion del asma. | |
| BR9915009A (pt) | Composto, composição farmacêutica, método de estimular a liberação do hormÈnio do crescimento da pituitária de um mamìfero, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| PE20011042A1 (es) | Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan |